News

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transition toward planned commerci.

07/08/2025

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive,.

06/25/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is enGene Holdings Inc. Common Stock (ENGN) a buy, sell, or hold?

enGene Holdings Inc. Common Stock (ENGN) can sell. Click on Rating Page for detail.

What is enGene Holdings Inc. Common Stock's stock price?

The price of enGene Holdings Inc. Common Stock (ENGN) is 3.31 and it was updated on 2025-07-12 07:00:22.

Is enGene Holdings Inc. Common Stock (ENGN) overvalued or undervalued?

Currently enGene Holdings Inc. Common Stock (ENGN) is in undervalued.

News

From:

To:

News
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade) enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges on positive LEGEND trial results, making this a high-risk, high-reward scenario. Wed, Jun. 18, 2025
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Amy Pott, Chief Global Commercialization Officer, with a grant date of June 16, 2025. The inducement award for Ms. Pott consists of a non-qualified stock option to purchase an aggregate 400,000 of the Company's common shares. The inducement awards fo. Tue, Jun. 17, 2025
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. “We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive Officer of enGene. “This positions us to stay on track for our planned trial updates across all cohorts in the second. Thu, Jun. 12, 2025
enGene Announces the Resignation of its Chief Medical Officer BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi's resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Prut. Wed, Jun. 04, 2025
enGene to Present at the Jefferies Global Healthcare Conference BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. A. Thu, May. 29, 2025

SEC Filings

SEC Filings
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 07/10/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 07/08/2025
enGene Holdings Inc. Common Stock (ENGN) - 3 SEC Filings 07/08/2025
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 06/16/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 06/12/2025
enGene Holdings Inc. Common Stock (ENGN) - 10-Q - Quarterly Report SEC Filings 06/12/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 06/10/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 06/09/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 06/05/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 06/04/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 06/04/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 05/29/2025
enGene Holdings Inc. Common Stock (ENGN) - 3 SEC Filings 05/29/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/28/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/27/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/23/2025
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 05/23/2025
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 05/19/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 05/16/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 05/14/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 05/12/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 05/12/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 05/09/2025
enGene Holdings Inc. Common Stock (ENGN) - DEF 14A SEC Filings 05/09/2025
enGene Holdings Inc. Common Stock (ENGN) - ARS SEC Filings 05/09/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 05/07/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 05/05/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 05/05/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 05/05/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 05/02/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 05/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 04/30/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/28/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/25/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 04/24/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 04/24/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/23/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 04/23/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/22/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/21/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/17/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 04/17/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/17/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/15/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 04/15/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 04/15/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 04/14/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/14/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 04/11/2025
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 04/10/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 04/07/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 04/07/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/04/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 04/03/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 04/03/2025
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 04/03/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/03/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 04/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 04/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 04/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 04/01/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/01/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 03/31/2025
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 03/28/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 03/27/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 03/27/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 03/26/2025
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 03/26/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 03/26/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 03/25/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 03/25/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/25/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/25/2025
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 03/24/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/24/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 03/21/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 03/21/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/19/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/19/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 03/18/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 03/17/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/17/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 03/13/2025
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 03/11/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 03/11/2025
enGene Holdings Inc. Common Stock (ENGN) - S-8 SEC Filings 03/10/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 03/10/2025
enGene Holdings Inc. Common Stock (ENGN) - 10-Q - Quarterly Report SEC Filings 03/10/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 03/07/2025
enGene Holdings Inc. Common Stock (ENGN) - AW SEC Filings 03/05/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 03/04/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 03/04/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 02/28/2025
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 02/28/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/28/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/27/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 02/27/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/26/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/25/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 02/25/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 02/25/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/24/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/21/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/20/2025
enGene Holdings Inc. Common Stock (ENGN) - 10-K/A - Current report SEC Filings 02/20/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 02/19/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/19/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 02/14/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 02/14/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 02/13/2025
enGene Holdings Inc. Common Stock (ENGN) - 40-17G SEC Filings 02/13/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 02/12/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 02/12/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 02/07/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 02/07/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 02/06/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 02/06/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/06/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 02/05/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 02/04/2025
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 01/31/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 01/30/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 01/30/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 01/29/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 01/29/2025
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 01/28/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 01/24/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 01/23/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 01/23/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 01/23/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 01/23/2025
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P/A SEC Filings 01/21/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 01/21/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 01/21/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 01/16/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 01/16/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 01/15/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 01/13/2025
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 01/10/2025
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 01/08/2025
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 01/07/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 01/03/2025
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 01/03/2025
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 01/03/2025
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 01/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 01/02/2025
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 01/02/2025
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 12/31/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/31/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 12/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 12/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 12/27/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 12/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 12/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 12/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 12/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 424B5 SEC Filings 12/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 12/19/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/19/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 12/19/2024
enGene Holdings Inc. Common Stock (ENGN) - 10-K - Current report SEC Filings 12/19/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 12/16/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 12/16/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 12/13/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 12/11/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/11/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 12/06/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 12/06/2024
enGene Holdings Inc. Common Stock (ENGN) - POS EX SEC Filings 12/06/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 12/06/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 12/06/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 12/05/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/05/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/05/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 12/05/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 12/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 11/29/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 11/29/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/29/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 11/27/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 11/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 11/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 11/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 424B3 SEC Filings 11/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 11/18/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 11/14/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 11/14/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 11/13/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 11/13/2024
enGene Holdings Inc. Common Stock (ENGN) - S-3 SEC Filings 11/13/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G SEC Filings 11/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 11/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 11/12/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 11/12/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 11/12/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 11/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 11/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 11/08/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 11/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 11/07/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 11/07/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 11/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 11/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 11/07/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 11/06/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 11/06/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 11/06/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 11/06/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 11/06/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13D/A SEC Filings 11/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 11/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 11/01/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 10/29/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/29/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 10/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 10/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 10/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 424B3 SEC Filings 10/28/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 10/25/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 10/25/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 10/25/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 10/25/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 10/24/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 10/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/24/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 10/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/23/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 10/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 10/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 10/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 3 SEC Filings 10/22/2024
enGene Holdings Inc. Common Stock (ENGN) - SCHEDULE 13G/A SEC Filings 10/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 10/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 10/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 10/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 424B3 SEC Filings 10/21/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13D/A SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 10/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/17/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 10/16/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 10/15/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/11/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/11/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 10/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/07/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 10/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 4 SEC Filings 10/01/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 09/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 09/30/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 09/27/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 09/27/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 09/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 424B3 SEC Filings 09/26/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 09/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 09/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 09/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 09/13/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 09/12/2024
enGene Holdings Inc. Common Stock (ENGN) - N-14/A SEC Filings 09/11/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 09/10/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 09/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 09/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 424B3 SEC Filings 09/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 10-Q - Quarterly Report SEC Filings 09/10/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 09/05/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-K - Current report SEC Filings 09/05/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 09/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 09/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 08/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 08/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/30/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 08/27/2024
enGene Holdings Inc. Common Stock (ENGN) - N-PX SEC Filings 08/27/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 08/27/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 08/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 08/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 08/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/16/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/15/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 08/15/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 08/15/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 08/14/2024
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 08/13/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 08/12/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 08/12/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 08/07/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 08/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 08/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 08/06/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 08/02/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 08/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 08/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/01/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 07/26/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 07/25/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 07/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 07/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 07/19/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 07/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 07/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 07/17/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 07/16/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 07/12/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 07/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 07/10/2024
enGene Holdings Inc. Common Stock (ENGN) - N-14 SEC Filings 07/09/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/09/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 07/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 07/08/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 07/03/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 07/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 07/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/02/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 07/02/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 07/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/01/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 06/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 06/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/28/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 06/27/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 06/27/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/26/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 06/26/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 06/25/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 06/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 06/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 06/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 06/17/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 06/17/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 06/14/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/13/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/12/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 06/11/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/11/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 06/10/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 06/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 06/10/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 06/07/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 06/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 06/06/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 06/04/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 05/29/2024
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 05/29/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 05/28/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 05/28/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 05/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 05/24/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 05/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 05/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 05/23/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 05/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 05/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 05/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 05/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 05/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 05/20/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 05/10/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 05/10/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 05/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 05/08/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 05/03/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 05/01/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 05/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 04/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 04/25/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 04/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 04/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 04/05/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 04/05/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 04/03/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 04/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 03/28/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 03/27/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 03/26/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 03/25/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/25/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 03/21/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/20/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 03/15/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 03/15/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 03/14/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/14/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/14/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/13/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/13/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 03/13/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 03/08/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 03/08/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 03/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 03/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 03/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 03/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 03/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 03/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 03/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 03/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 03/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 02/29/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 02/28/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/27/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/26/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 02/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 02/23/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/22/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/16/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/13/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 02/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 02/09/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 02/09/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/09/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 02/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 02/07/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 02/07/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 02/07/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 02/06/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 02/06/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 02/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 02/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 02/01/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 01/30/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 01/29/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 01/26/2024
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 01/25/2024
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 01/25/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 01/24/2024
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 01/22/2024
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 01/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 01/18/2024
enGene Holdings Inc. Common Stock (ENGN) - 40-17G SEC Filings 01/18/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 01/12/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 01/12/2024
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 01/12/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 01/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 01/10/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 01/09/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 01/08/2024
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 01/08/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR/A SEC Filings 01/05/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 01/04/2024
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 01/04/2024
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 01/04/2024
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/29/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 12/28/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 12/27/2023
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 12/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 12/26/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 12/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 12/21/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 12/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/19/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 12/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/15/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/15/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 12/15/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 12/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 12/12/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/11/2023
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 12/11/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 12/08/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/08/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 12/07/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 12/06/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 12/06/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 12/04/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 12/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 12/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 12/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 12/01/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 11/28/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 11/28/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/28/2023
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 11/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 11/24/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 11/24/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/24/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 11/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 11/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 11/17/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 11/14/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 11/13/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 11/13/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 11/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 11/09/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 11/07/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 11/07/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/03/2023
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 11/03/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 11/02/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 11/02/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 11/02/2023
enGene Holdings Inc. Common Stock (ENGN) - 25-NSE SEC Filings 11/02/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P/A SEC Filings 10/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 10/27/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 10/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 10/26/2023
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 10/26/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 10/19/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/18/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 10/17/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/16/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 10/16/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 10/13/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 10/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 10/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 10/12/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/11/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/11/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 10/10/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 10/06/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 10/06/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 10/06/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/06/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 10/05/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 10/04/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 10/04/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 10/03/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 10/02/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 09/29/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 09/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 09/26/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 09/25/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 09/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 09/20/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 09/19/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 09/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 09/15/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 09/14/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 09/13/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 09/13/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 09/07/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 09/07/2023
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 09/07/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 09/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 09/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 09/01/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 08/28/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 08/25/2023
enGene Holdings Inc. Common Stock (ENGN) - N-PX SEC Filings 08/25/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 08/24/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/24/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 08/23/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 08/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 08/18/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 08/17/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 08/15/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P/A SEC Filings 08/14/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/14/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 08/11/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 08/08/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 08/03/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 08/03/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 08/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 08/01/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 07/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 07/25/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 07/21/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 07/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 07/20/2023
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 07/19/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 07/17/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/17/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 07/14/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/14/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 07/14/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 07/12/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 07/07/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 07/07/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSRS SEC Filings 07/03/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 07/03/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 07/03/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/30/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 06/30/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/30/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 06/28/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/28/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 06/27/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 06/26/2023
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 06/26/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 06/23/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 06/23/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 06/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 06/22/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 06/22/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 06/21/2023
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 06/16/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 06/15/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CEN SEC Filings 06/14/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 06/14/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 06/09/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G/A SEC Filings 06/08/2023
enGene Holdings Inc. Common Stock (ENGN) - SC 13G SEC Filings 06/08/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CEN/A SEC Filings 06/07/2023
enGene Holdings Inc. Common Stock (ENGN) - CERT SEC Filings 06/07/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/07/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/06/2023
enGene Holdings Inc. Common Stock (ENGN) - 8-A12B SEC Filings 06/02/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 06/02/2023
enGene Holdings Inc. Common Stock (ENGN) - N-CSR SEC Filings 06/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497K SEC Filings 06/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 497 SEC Filings 06/01/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BPOS SEC Filings 05/30/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/26/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/25/2023
enGene Holdings Inc. Common Stock (ENGN) - 485BXT SEC Filings 05/25/2023
enGene Holdings Inc. Common Stock (ENGN) - NPORT-P SEC Filings 05/24/2023
enGene Holdings Inc. Common Stock (ENGN) - 497J SEC Filings 05/19/2023
enGene Holdings Inc. Common Stock (ENGN) - 24F-2NT SEC Filings 05/19/2023
enGene Holdings Inc. Common Stock (ENGN) - 485APOS SEC Filings 05/18/2023

Press Releases

StockPrice Release
Engene announces board and leadership appointments to support commercial readiness 07/08/2025
Fda grants rmat designation for engene's detalimogene, enabling potential for expedited review in high-risk, non-muscle invasive bladder cancer 06/25/2025
Engene reports inducement grants under nasdaq listing rule 5635(c)(4) 06/17/2025
Engene reports second quarter 2025 financial results and provides business update 06/12/2025
Engene announces the resignation of its chief medical officer 06/04/2025
Engene to present at the jefferies global healthcare conference 05/29/2025
Engene names amy pott as chief global commercialization officer 05/28/2025
Engene to participate in upcoming investor conferences 04/28/2025
Engene reports inducement grants under nasdaq listing rule 5635(c)(4) 04/04/2025
Engene to present at the stifel 2025 virtual targeted oncology forum 04/01/2025
Engene reports first quarter 2025 financial results and provides business update 03/10/2025
Engene reports inducement grants under nasdaq listing rule 5635(c)(4) 01/31/2025
Engene to present three posters at the 2025 asco genitourinary cancers symposium (asco gu) highlighting the ongoing clinical development of detalimogene voraplasmid for the treatment of non-muscle invasive bladder cancer (nmibc) 01/30/2025
Engene reports inducement grants under nasdaq listing rule 5635(c)(4) 12/30/2024
Engene reports full year 2024 financial results and provides a business update 12/19/2024
Engene to participate in upcoming investor conferences 11/25/2024
Engene to participate in guggenheim's inaugural healthcare innovation conference 11/05/2024
Engene announces $60 million private placement financing 10/25/2024
Engene reports inducement grant under nasdaq listing rule 5635(c)(4) 10/22/2024
Engene appoints joan connolly as chief technology officer and anthony cheung, ph.d., as chief scientific officer 10/21/2024
Engene reports inducement grants under nasdaq listing rule 5635(c)(4) 10/01/2024
Detalimogene demonstrates 71% complete response rate at any time in preliminary analysis of legend pivotal cohort 09/26/2024
Engene to participate in upcoming investor conferences 08/28/2024
Engene reports second quarter 2024 financial results and provides a business update 06/14/2024
Engene to present at the jefferies global healthcare conference 05/29/2024
Engene announces the election of paul hastings and wouter joustra to its board of directors 05/15/2024
Engene to present details of its pivotal phase 1/2 legend study of eg-70 in bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ at the american urology association 2024 annual meeting 05/02/2024
/c o r r e c t i o n -- engene inc./ 04/09/2024
Engene reports first quarter 2024 financial results and recent corporate progress 03/11/2024
Engene to present at the leerink partners global biopharma conference 03/05/2024
Engene announces oversubscribed $200 million private placement financing 02/14/2024
Engene announces leadership succession plan 02/14/2024
Engene appoints lee giguere as chief legal officer and corporate secretary 01/30/2024
Engene reports full year 2023 financial results and recent operational progress 01/29/2024
Engene announces expanded $50 million debt facility with hercules capital 12/22/2023
Engene appoints lota s. zoth, cpa, as member of the board of directors 12/19/2023
Engene appoints ryan daws as chief financial officer 11/29/2023

More Headlines

News
enGene Names Amy Pott as Chief Global Commercialization Officer BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to. 05/28/2025
enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,. 04/28/2025
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price. 04/04/2025
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene e. 04/01/2025
enGene Reports First Quarter 2025 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. “With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026,” said Ron Cooper, Chief Executive Officer o. 03/10/2025
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential. 02/27/2025
Best Momentum Stocks to Buy for February 19th NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024. 02/19/2025
New Strong Buy Stocks for February 19th GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024. 02/19/2025
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to. 01/31/2025
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced three poster presentations at the 2025. 01/30/2025
How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77% The average of price targets set by Wall Street analysts indicates a potential upside of 238.8% in enGene Holdings Inc. (ENGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 01/09/2025
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to. 12/30/2024
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why enGene Holdings Inc. (ENGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). 12/20/2024
enGene Reports Full Year 2024 Financial Results and Provides a Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), announced its financial results for the full year end. 12/19/2024
enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet that the FDA gives ENGN a generous approval on single-arm data. Considering the current price, and their favorable financial position, my outlook from here for the company is very positive. 12/15/2024
Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks enGene Holdings Inc. (ENGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. 12/13/2024
enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Alex Nichols, Ph.D., Chief Strategy. 11/25/2024
enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Officer. 11/05/2024
enGene Announces $60 Million Private Placement Financing BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of. 10/25/2024
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of an inducement equity award t. 10/22/2024
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chie. 10/21/2024
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of inducement equity awards to. 10/01/2024
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). Today, the Company announced preliminary data from 21. 09/26/2024
enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that the Company will participate in several upcoming inv. 08/28/2024
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the second quarter ended April 30, 2024, and provided a business update. “Our $200 million private placement in February positioned us well to execute our p. 06/14/2024
enGene to Present at the Jefferies Global Healthcare Conference BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET. A live webcast of the presentation can. 05/29/2024
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serv. 05/15/2024
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations BOSTON and MONTREAL , May 2, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas. The presentation, "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)," will be given by Dr. Gordon Brown, Director of the Center for Advanced Therapeutics and Urologic Oncology, Summit Health-South, at 10:30 a.m. 05/02/2024
/C O R R E C T I O N -- enGene Inc./ In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by enGene Inc., the headline was incorrectly transmitted by CNW. The headline should read "enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development". 04/09/2024
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private financing, expected to extend cash runway into 2027 BOSTON and MONTREAL , March 11, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024. "This is an exciting time for the Company as we move closer to realizing our vision of mainstreaming genetic medicines to address diseases with high unmet clinical needs. 03/11/2024
enGene To Present at the Leerink Partners Global Biopharma Conference BOSTON and MONTREAL , March 5, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on March 13, 2024, at 8:40 a.m. ET. A live webcast of the presentation can be accessed under the Investors section of the enGene website at www.engene.com/presentations and will be archived there for 90 days. 03/05/2024
enGene Announces Oversubscribed $200 Million Private Placement Financing Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 BOSTON and MONTREAL , Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that it has agreed to sell 20 million of its common shares at a price per share of $10.00, representing a 31% premium over the closing price on February 13, 2024. The financing is expected to close on February 16, 2024, subject to customary closing conditions. 02/14/2024
enGene Announces Leadership Succession Plan BOSTON and MONTREAL , Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that due to personal family and health reasons, Jason Hanson intends to resign from his role as Chief Executive Officer and a member of the Board of Directors upon the appointment of a successor CEO. The Board of Directors has initiated a search for his successor. 02/14/2024
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70 BOSTON and MONTREAL , Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary. "I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer," said Jason D. 01/30/2024
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with interim data expected mid this year Completed a reverse merger transaction with Forbion European Acquisition Corp (FEAC), launched as a public company on November 1, 2023, and completed an upsized PIPE financing Combined transactions resulted in net proceeds of approximately $109 million Closed an expanded $50M debt facility with Hercules Capital in December 2023; extends cash runway into Q2 2025 BOSTON and MONTREAL , Jan. 29, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) (or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the fiscal year ended October 31, 2023 and provided a corporate update. "During 2023, enGene made substantial progress advancing our lead program, EG-70 (detalimogene voraplasmid), in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. 01/29/2024
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital BOSTON and MONTREAL , Dec. 22, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced today that it has entered into an amended USD $50 million loan agreement (the "Loan Agreement") with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). Under the Loan Agreement, which has a term of four years, $22.5 million has been advanced to enGene under a non-revolving term loan and, subject to certain clinical and financial milestones, up to a further $27.5 million in loan proceeds may be available subject to satisfaction of certain terms and conditions. 12/22/2023
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors BOSTON and MONTREAL , Dec. 19, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lota S. Zoth, CPA, as a member of the Board of Directors and Audit Committee Chair. 12/19/2023
enGene Appoints Ryan Daws as Chief Financial Officer BOSTON and MONTREAL , Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development. "I am delighted to welcome Ryan to enGene at a critical time in our growth, as we move forward as a public company and work to advance our ongoing pivotal-stage EG-70 clinical study in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)," said Jason D. 11/29/2023

Unlock

ENGN Ratings Summary

ENGN Quant Ranking